Who depends on this research?

About 39 million people worldwide live with HIV, according to widely cited UNAIDS figures. Antiretroviral therapy has converted HIV from a near-certain death sentence into a manageable chronic condition for those with reliable access to medication. Major gaps remain, however. A preventive vaccine does not exist. Many low- and middle-income countries still struggle to deliver consistent treatment.

NIH-funded science underpins much of the work addressing these gaps, including studies of long-acting injectables, broadly neutralizing antibodies, and gene-editing approaches aimed at functional cures. The agency's clinical trials networks, such as the AIDS Clinical Trials Group, run studies that often enroll participants across multiple continents.

Why is Think Global Health focused on this?

Think Global Health is a publication affiliated with the Council on Foreign Relations, a nonpartisan US policy organization. The outlet tends to cover how health policy decisions made in Washington ripple outward to other countries. Its decision to highlight NIH budget cuts suggests concern that US funding decisions carry international consequences, particularly in regions where American grants support treatment access and prevention campaigns.

That international angle is significant. PEPFAR, the President's Emergency Plan for AIDS Relief, remains the largest US global health initiative focused on a single disease and has credited NIH research for the scientific foundations of its programs. Reductions in NIH funding would not automatically translate into PEPFAR cuts, but scientists worry that a weakened domestic research base would slow the pipeline of tools that global programs rely on.

What remains uncertain

The precise scale of the cuts flagged by Think Global Health, along with the programs most affected, is not visible in the headline excerpt circulating this week. The publication's full report would offer the detail needed to gauge real-world impacts.

What researchers have said repeatedly in recent years, even before this latest round of attention, is that sustained flat funding effectively amounts to a cut once inflation is factored in. Laboratory supplies, salaries, and overhead costs have all risen faster than the consumer price index. Some investigators report postponing equipment purchases, deferring admissions of new graduate students, or trimming international field sites. A fresh round of explicit budget reductions would intensify those pressures, with consequences for an HIV research enterprise that took more than four decades to build.